Cargando…

Identification of MGMT Downregulation Induced by miRNA in Glioblastoma and Possible Effect on Temozolomide Sensitivity

Glioblastoma multiforme (GBM) remains one of the tumors with the worst prognosis. In recent years, a better overall survival (OS) has been described in cases subjected to Gross Total Resection (GTR) that were presenting hypermethylation of Methylguanine-DNA methyltransferase (MGMT) promoter. Recentl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cardia, Andrea, Epistolio, Samantha, Zaed, Ismail, Sahnane, Nora, Cerutti, Roberta, Cipriani, Debora, Barizzi, Jessica, Spina, Paolo, Stefanini, Federico Mattia, Cerati, Michele, Balbi, Sergio, Mazzucchelli, Luca, Sessa, Fausto, Pesce, Gianfranco Angelo, Reinert, Michael, Frattini, Milo, Marchi, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004383/ https://www.ncbi.nlm.nih.gov/pubmed/36902848 http://dx.doi.org/10.3390/jcm12052061

Ejemplares similares

The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation
por: Marchi, Francesco, et al.
Publicado: (2020)

Functional and clinical significance of ROR1 in lung adenocarcinoma
por: Giovanna, Schiavone, et al.
Publicado: (2020)

Correction to: Functional and clinical significance of ROR1 in lung adenocarcinoma
por: Schiavone, Giovanna, et al.
Publicado: (2020)

Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab
por: Epistolio, Samantha, et al.
Publicado: (2021)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

Overview of recent advances in molecular analysis for diagnosing early stage lung cancer nodules
por: Frattini, Milo, et al.
Publicado: (2021)

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas, Reena P, et al.
Publicado: (2012)

Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer
por: Dazio, Giulia, et al.
Publicado: (2022)

Use Of Temozolomide In Parathyroid Carcinoma With Negative Mgmt Promoter Methylation
por: Reddy, Niyoti, et al.
Publicado: (2021)

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
por: Rahman, Mohummad Aminur, et al.
Publicado: (2019)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
por: ABE, Hideaki, et al.
Publicado: (2018)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

A Pilot, Prospective, Observational Study to Investigate the Value of NGS in Liquid Biopsies to Predict Tumor Response After Neoadjuvant Chemo-Radiotherapy in Patients With Locally Advanced Rectal Cancer: The LiBReCa Study
por: Roesel, Raffaello, et al.
Publicado: (2022)

Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy
por: Cefalì, Marco, et al.
Publicado: (2022)

A qPCR technology for direct quantification of methylation in untreated DNA
por: Bendixen, Kamilla Kolding, et al.
Publicado: (2023)

Role of Enhanced Recovery after Surgery (ERAS) Protocol in the Management of Elderly Patients with Glioblastoma
por: Zaed, Ismail, et al.
Publicado: (2023)

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
por: Dunn, J, et al.
Publicado: (2009)

Valproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma Cells
por: Ryu, Chung Heon, et al.
Publicado: (2012)

Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells
por: Qiu, Zhi-Kun, et al.
Publicado: (2014)

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
por: Chen, Xiaoyue, et al.
Publicado: (2018)

The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma
por: Jovanović, Nikola, et al.
Publicado: (2019)

The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma
por: Xu, Haoyue, et al.
Publicado: (2022)

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
por: Melguizo, Consolación, et al.
Publicado: (2012)

Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
por: Castro, Michael, et al.
Publicado: (2021)

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
por: Hassel, J C, et al.
Publicado: (2010)

Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital
por: Egaña, Larraitz, et al.
Publicado: (2020)

On the Critical Issues in Temozolomide Research in Glioblastoma: Clinically Relevant Concentrations and MGMT-independent Resistance
por: Stepanenko, Aleksei A., et al.
Publicado: (2019)

Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated MGMT
por: Álvarez-Torres, María del Mar, et al.
Publicado: (2021)

BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
por: Tancredi, Alessandro, et al.
Publicado: (2022)

Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma
por: Han, Xinyu, et al.
Publicado: (2023)

Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
por: Wang, Ke, et al.
Publicado: (2017)

A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation
por: Calegari, M A, et al.
Publicado: (2017)

Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status
por: Wu, Qiong, et al.
Publicado: (2023)

Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3
por: Forcella, Matilde, et al.
Publicado: (2017)

Role of NEU3 Overexpression in the Prediction of Efficacy of EGFR-Targeted Therapies in Colon Cancer Cell Lines
por: Bovio, Federica, et al.
Publicado: (2020)

Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
por: Cekani, Elona, et al.
Publicado: (2022)

Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression
por: Perazzoli, Gloria, et al.
Publicado: (2015)

Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2
por: Yi, Guo-zhong, et al.
Publicado: (2019)

Blocking MAPK/ERK pathway sensitizes hepatocellular carcinoma cells to temozolomide via downregulating MGMT expression
por: Li, Qiang, et al.
Publicado: (2020)

CORRIGENDUM FOR “Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of theMGMT Gene”
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i2t0jo8a3mvc2l7d2l8qtuiit3